Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises IRLAB Therapeutics in connection with a directed share issue
Mandate

Vinge advises IRLAB Therapeutics in connection with a directed share issue

May 24, 2018

The board of directors of IRLAB Therapeutics has, on the basis of an authorisation granted from the annual general meeting, resolved on a directed new issue of shares, whereby IRLAB Therapeutics will raise proceeds of SEK 138,6 million, before issue costs.

The share issue is directed to a number of selected institutional investors in Sweden and the US. 
 
IRLAB Therapeutics is a research and development company, listed on Nasdaq First North Premier, focused on development of novel therapies for the treatment of neurodegenerative diseases, in particular Parkinson’s disease and dementia.
 
Vinge’s team has consisted of Dain Hård Nevonen, Sofie Bjärtun and Hampus Olsson
 
 

Related

Vinge advises Intrum on its EUR 4.48 billion recapitalisation transaction

 Intrum AB and its subsidiaries have completed a comprehensive and strategic recapitalisation transaction aimed at strengthening the company's balance sheet and securing its long-term financial stability. The transaction involves a restructuring of Intrum's existing debt portfolio of approximately EUR 4.48 billion and includes, among other things, an extension of loan maturities, write-downs of existing debt instruments, the injection of new capital from certain of the company's noteholders, and a share issue to existing noteholders. The recapitalisation transaction was implemented through a pre-packaged Chapter 11 process in the United States and a Swedish company reorganisation.
August 25, 2025

Vinge advises Neptuniplan Maritime in financing of ANCS acquisition

 Vinge has advised Neptuniplan Maritime Holding AB in connection with entering into a more than EUR 133 000 000 facilities agreement with Citibank, Danske Bank and Nordea for the purpose of, among other things, financing its acquisition of Wärtsilä’s Automation, Navigation and Control Systems (ANCS) business. Operations will be continuing under NACOS Marine, who provides, among other things, advanced solutions in vessel navigation, automation, and control systems, as well as adaptive autopilots and Guidance Marine, a leader in position reference sensor technology for dynamic positioning and maritime safety.
August 25, 2025

Vinge has advised HealthCap on the establishment of HealthCap IX

 HealthCap IX has held its final closing, raising total commitments in excess of the target from a diverse investor base comprising established institutions, pension funds, and renowned investors within the life sciences sector. The strong support reflects continued confidence in HealthCap’s strategy and proven track record.
August 22, 2025